Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 16, 2016 - Issue 1
Submit an article Journal homepage
288
Views
10
CrossRef citations to date
0
Altmetric
Special Report

Dopamine transporter scanning in the evaluation of patients with suspected Parkinsonism: a case-based user’s guide

Federico Rodriguez-PorcelDepartment of Neurology, UC Neuroscience Institute, University of Cincinnati, Cincinnati, Ohio, USA;Gardner Family Center for Parkinson’s Disease and Movement Disorders, Cincinnati, Ohio, USA
,
Sheheryar JamaliDepartment of Neurology, UC Neuroscience Institute, University of Cincinnati, Cincinnati, Ohio, USA;Gardner Family Center for Parkinson’s Disease and Movement Disorders, Cincinnati, Ohio, USA
,
Andrew P. DukerDepartment of Neurology, UC Neuroscience Institute, University of Cincinnati, Cincinnati, Ohio, USA;Gardner Family Center for Parkinson’s Disease and Movement Disorders, Cincinnati, Ohio, USA
&
Alberto J. EspayDepartment of Neurology, UC Neuroscience Institute, University of Cincinnati, Cincinnati, Ohio, USA;Gardner Family Center for Parkinson’s Disease and Movement Disorders, Cincinnati, Ohio, USACorrespondence[email protected]
Pages 23-29 | Published online: 02 Dec 2015

References

  • Tatsch K, Poepperl G. Nigrostriatal dopamine terminal imaging with dopamine transporter SPECT: an update. J Nucl Med. 2013;54(8):1331–1338.
  • Bajaj N, Hauser RA, Grachev ID. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2013;84(11):1288–1295.
  • Brigo F, et al. Differentiating drug-induced parkinsonism from Parkinson’s disease: an update on non-motor symptoms and investigations. Parkinsonism Relat Disord. 2014;20(8):808–814.
  • Gaig C, et al. 123I-Ioflupane SPECT in the diagnosis of suspected psychogenic parkinsonism. Mov Disord. 2006;21(11):1994–1998.
  • Batla A, et al. Patients with scans without evidence of dopaminergic deficit: a long-term follow-up study. Mov Disord. 2014;29(14):1820–1825.
  • Benamer TS, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord. 2000;15(3):503–510.
  • Marshall VL, et al. Parkinson’s disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord. 2009;24(4):500–508.
  • de la Fuente-Fernandez R. Role of DaTSCAN and clinical diagnosis in Parkinson disease. Neurology. 2012;78(10):696–701.
  • Adler CH, et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology. 2014;83(5):406–412.
  • Selikhova M, et al. Neuropathological findings in benign tremulous parkinsonism. Mov Disord. 2013;28(2):145–152.
  • Deuschl G. Benign tremulous Parkinson’s disease: a misnomer? Mov Disord. 2013;28(2):117–119.
  • Cummings JL, et al. Effective and efficient diagnosis of parkinsonism: the role of dopamine transporter SPECT imaging with ioflupane I-123 injection (DaTscan). Am J Manag Care. 2014;20(5 Suppl): S97–109.
  • Schneider SA, et al. Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord. 2007;22(15):2210–2215.
  • Parkinson Progression Marker Initiative. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol. 2011;95(4):629–635.
  • Utiumi MA, et al. Dopamine transporter imaging in clinically unclear cases of parkinsonism and the importance of scans without evidence of dopaminergic deficit (SWEDDs). Arq Neuropsiquiatr. 2012;70(9):667–673.
  • Ba F, Martin WR. Dopamine transporter imaging as a diagnostic tool for parkinsonism and related disorders in clinical practice. Parkinsonism Relat Disord. 2015;21(2):87–94.
  • Marshall VL, et al. Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nucl Med Commun. 2006;27(12):933–937.
  • Citrome L. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? . Clin Schizophr Relat Psychoses. 2012;6(2):76–85.
  • Hallett M. Psychogenic parkinsonism. J Neurol Sci. 2011;310(1–2):163–165.
  • Benaderette S, et al. Psychogenic parkinsonism: a combination of clinical, electrophysiological, and [(123)I]-FP-CIT SPECT scan explorations improves diagnostic accuracy. Mov Disord. 2006;21(3):310–317.
  • Seibyl J, et al. Neuroimaging over the course of Parkinson’s disease: from early detection of the at-risk patient to improving pharmacotherapy of later-stage disease. Semin Nucl Med. 2012;42(6):406–414.
  • Covington MF, et al. The semicolon sign: dopamine transporter imaging artifact from head tilt. J Nucl Med Technol. 2013;41(2):105–107.
  • Lavalaye J, et al. Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med. 2000;27(7):867–869.
  • Djang DS, et al. SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. J Nucl Med. 2012;53(1):154–163.
  • Seibyl J, et al. The role of neuroimaging in the early diagnosis and evaluation of Parkinson’s disease. Minerva Med. 2005;96(5):353–364.
  • Fahn S, Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson’s disease? J Neurol. 2005;252(Suppl 4):IV37–IV42.
  • Hauser RA, Grosset DG. [123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromes. J Neuroimaging. 2012;22(3):225–230.
  • Cilia R, et al. Reversible dopamine transporter reduction in drug-induced parkinsonism. Mov Disord. 2014;29(4):575–577.
  • Kraemmer J, et al. Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts. Mov Disord. 2014;29(14):1767–1773.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.